Flomics Biotech

Direct 

• Promoting innovation in the healthcare system: Flomics is developing a cutting-edge technology capable of detecting cancer at its earliest stages with a simple blood test, eliminating the need for long and complex procedures and making cancer screening more accessible. The solution by Flomics is the result of successful research and innovation in the fields of oncology, genetics and bioinformatics, with validation of a liquid biopsy technology that is non-invasive, precise and offers early-state detection for five types of cancer (breast, lungs, prostate, pancreas and colon). With the work enabled through this loan, Flomics intends to continue building a platform of cancer diagnosis that works with databases and machine learning models to reach a sensitivity of 95% - while current liquid biopsies are likely to miss around 48% of cancers due to low sensitivity in early stages. 
• Creation of specialized jobs and enhancing scientific dissemination: this loan will result in ten new specialized positions at Flomics, primarily in R&D, bioinformatics, clinical development, and business operations. This expansion will enhance the company’s capacity to process patient samples, optimize AI and data analysis pipelines, and prepare for clinical trials and product certification. It will also lead to new publications and intellectual property, and to advanced diagnostic know-how, accelerating the path to market for multi-cancer early detection tests. 

Indirect 

• Contribution to increase patients' survival rates and quality of life: when cancers are diagnosed at advanced stages, only about 20% of patients survive beyond five years. With early detection, survival rates can increase to 80% of patients surviving beyond five years, often with less aggressive treatments and a better quality of life. Flomics aims to reduce late-stage cancer diagnoses by up to 50%, depending on cancer type and screening coverage, through earlier detection, identifying cancer when it is still curable. Treatments for early-stage cancers are typically more affordable, making early cancer detection more accessible and routine for patients. 
• Improvement in resources use in healthcare systems: early cancer diagnosis contributes to reducing the burden on healthcare systems, since it reduces the need for complex and expensive treatments such as surgery, chemotherapy, hospital stays, and long-term care. Early detection can reduce treatment costs by up to 70% and free-up medical capacity for prevention and follow-up care. By shifting diagnosis from late to early stages, the technology can contribute to lower overall cancer management costs by 30–50% per patient and ease the workload on oncologists, pathologists, and hospital infrastructure. 
• Improving quality of prevention in women’s health: women often face high rates of false-positive cancer test results, studies show that 50–60% of women undergoing regular breast-cancer screening experience at least one false alarm. Flomics’ Sentinel addresses this issue by analyzing molecular signatures in blood rather than relying on imaging. The Sentinel test is designed to deliver higher specificity and reduce unnecessary follow-up procedures, ensuring equal accuracy across men and women, helping to reduce the diagnostic burden that disproportionately affects women. 

Flomics Biotech is a biotechnology company founded in 2018 in Barcelona by a team of leading researchers and entrepreneurs from the Centre for Genomic Regulation (CRG) and the Universitat Pompeu Fabra (UPF). With a strong track record in scientific innovation and startup creation. The team launched Flomics with a clear mission: to make early disease detection simple, accurate and accessible through a single blood test.

Cancer is still too often diagnosed at advanced stages, when treatments are less effective and survival rates drop dramatically. Flomics aims to change this reality. Their flagship product, Sentinel™, is a non-invasive liquid biopsy test that analyzes tiny cell-free RNA (cf-RNA) signals circulating in the blood to detect early signs of cancer. In pre-clinical studies carried out with partners such as Hospital Clínic de Barcelona and the Biobanco del Sistema Público de Salud de Andalucía, Sentinel™ showed unprecedented performance, detecting 81% of Stage I cancers, a level of accuracy rarely achieved in early detection technologies.

In parallel with Flomic's diagnostic development, they are already commercialising access to its cf-RNA technology for research use only (RUO), generating recurring revenue and validating the market’s interest. Through their own bioinformatics cloud platform Stratus® and genomics services, Flomic supports hospitals, universities and research institutes across Europe. Current customers and collaborators include institutions such as Hospital Sant Joan de Déu, the Instituto Português de Oncologia (IPO), Vall d’Hebron, and FISABIO, among others. These collaborations also allow the promoter to expand their impact into areas such as rare diseases, minimal residual disease, and therapy selection.

Flomics is entering a new phase of growth. Building on scientific results and commercial traction, the promoter is preparing a 6 million euro Series A round, expected to close in Q1 2026. This financing will support the start of clinical trials, regulatory activities, team expansion, and the next steps toward making early-detection tests available to patients and healthcare systems.

Their long-term vision is to transform healthcare into a more preventive, efficient and patient-centred model, where diseases are detected earlier, treatments are less aggressive, and outcomes are significantly improved.